Highlights From ASCO GI 2023

John L. Marshall, MD


February 07, 2023

Dr John Marshall, director of the Ruesch Center for the Cure of Gastrointestinal Cancers, highlights key findings presented at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

First, Dr Marshall focuses on the SPOTLIGHT study, which examined the investigational monoclonal antibody zolbetuximab for patients with gastric and gastroesophageal junction adenocarcinoma who are Claudin 18.2–positive. The study found that first-line treatment with zolbetuximab combined with leucovorin, fluorouracil, and oxaliplatin led to significantly longer progression-free and overall survival.

Next, Dr Marshall discusses updates from two studies that investigated the advantages of chemotherapy plus nivolumab for patients with esophageal squamous cell carcinoma, especially those with higher programmed death–ligand 1 status.

He also reports on the NAPOLI-3 study, which compared a novel chemotherapy regimen with standard therapy in patients with metastatic pancreatic ductal adenocarcinoma.

Finally, Dr Marshall discusses postoperative testing of circulating tumor DNA and how results can affect the timing of adjuvant chemotherapy for patients with resected colorectal cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.